Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?

ABSTRACT:

Background

This study assessed the prognostic value of HE4 marker measurements at various stages of first-line chemotherapy for ovarian cancer.

Methods

The study consisted of 90 ovarian cancer patients, including 48 women undergoing primary surgical treatment and 42 patients qualified for neoadjuvant chemotherapy. Each patient underwent HE4 and CA 125 level measurements at the time of diagnosis and subsequently as follows: after surgical treatment, after the third course of adjuvant chemotherapy, before interval cytoreductive surgery and after chemotherapy. The HE4 value was assessed based on the PSF, OS, DFS, surgical outcome, two-year survival and platinum sensitivity.

Results

Preoperative HE4 levels were a predictor of platinum sensitivity (AUC- 0.644; p = 0.035) a

SUBMITTER: Chudecka-Glaz A 

PROVIDER: S-EPMC5870956 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature